Intravenous immunoglobulin (IVIg) has been used in the treatment of several autoimmune and inflammatory diseases. However, its mechanism of action remains incompletely understood. Here, we investigated the possibility that IVIg induces its anti-inflammatory effects through activating Fc␥ receptors bearing an immunoreceptor tyrosine-based activation motif (ITAM) in the FcR␥ signaling adaptor. Recently, the concept of inhibitory ITAM (ITAMi) has emerged as a new means to negatively control the immune response. We found that interaction of 
Introduction
Intravenous immunoglobulin (IVIg) is used not only for treatment of immune deficiencies, but also constitutes a therapeutic option in a large number of autoimmune, allergic, and inflammatory diseases. 1, 2 Different mechanisms have been suggested as responsible for the anti-inflammatory activity of IVIg such as, its content of natural polyreactive Abs reactive, its ability to stimulate or block cellular receptors for immunoglobulins (Igs; Fc receptors, or FcRs), inhibition of the complement cascade, modulation of cytokine production, neutralization of auto-antibodies, and differential antibody glycosylation. 1, [3] [4] [5] [6] Fc␥R exist in multiple isoforms comprising high-affinity and low-affinity receptors. In humans, there is one high-affinity IgG receptor, Fc␥RI (CD64), and 2 families of low-affinity IgG receptors, Fc␥RIIA, IIB, and IIC (CD32), and Fc␥RIIIA and IIIB (CD16). Fc␥RI and Fc␥RIIIA are associated with the common signaling adaptor FcR␥, whereas Fc␥RIIA, Fc␥RIIB and Fc␥RIIC are single-chain receptors and Fc␥RIIIB is a glycosyl-phosphatidyl inositol (GPI)-anchored receptor. In mice, there is no homolog to Fc␥RIIA and Fc␥RIIIB, but they express another FcR␥-associated receptor, the Fc␥RIV, that is not found in humans. 7 The FcR␥ chain contains a tyrosine-based activation motif (ITAM) and is the prime effector of the proinflammatory activity of IgG in inflammatory and autoimmune diseases. Cross-linking of activating Fc␥Rs, such as Fc␥RI, Fc␥RIII and Fc␥RIV, by immune complexes, launches transmembrane signaling after phosphorylation of ITAM tyrosine residues in the receptor-associated FcR␥ subunit by kinases of the Src family. 8, 9 For example, Fc␥RIII multimerization exacerbates inflammation in several models of immune complex-mediated diseases. [10] [11] [12] By contrast, Fc␥RIIB, which is conserved in mice and humans, is a single-chain inhibitory Fc␥R. Fc␥RIIB contains tyrosine-based inhibition motif (ITIM) in its cytoplasmic region. 13 Inhibition was shown to depend on the isotype of IgG and on Fc␥RIIB expression levels. Up-regulation of the latter was proposed as one of the mechanisms for the anti-inflammatory action of IVIg therapy. 1 Fc␥R anti-inflammatory activities of IVIg are mediated through both Fc␥RIIB-and/or Fc␥RIIIA-dependent and Fc␥R-independent mechanisms. [14] [15] [16] However, mechanisms of action of IVIg through activating Fc␥RIII are not yet fully elucidated.
The classic concept of the functional polarity of ITIM and ITAM motifs has been recently reevaluated. Several studies have demonstrated that ITAM can also initiate inhibitory signaling toward heterologous receptors. [17] [18] [19] This active inhibitory signaling by ITAM-bearing receptors was named inhibitory ITAM (ITAMi). 18 Thus, the Fc␣RI that is associated with the ITAM-bearing adaptor FcR␥, was found to act as a bifunctional module which, depending on the type of interaction with its ligand, induces either activating or inhibitory cell signaling. Although multivalent cross-linking of Fc␣RI with IgA-immune complexes induced proinflammatory signaling, monovalent Fc␣RI targeting with IgA in the absence of antigen can trigger inhibitory signals toward a whole array of cellular functions such as IgG-dependent phagocytosis, IgEdependent degranulation, and TLR-or cytokine-mediated responses. 20, 21 Strikingly, monomeric IgA binding induces weak ITAM-phosphorylation, transient recruitment of Syk followed by stable recruitment of SHP-1, whereas multivalent aggregation promotes strong ITAM phosphorylation with stable Syk recruitment. Recruitment of SHP-1 in the ITAMi configuration promotes the actin depolymerization-dependent "trapping" of Fc␣RI and of the targeted activating receptors within the same lipid rafts, which is followed by the appearance of intracellular inhibisome clusters. 22 Recently, Fc␥RIII, on direct interaction with Escherichia coli, was shown to launch an FcR␥-dependent inhibitory pathway that down-regulates MARCO scavenger receptor signaling, thereby preventing E coli phagocytosis. 23 Based on these observations we hypothesized that the interaction between FcR␥-associated Fc␥RIII and its natural ligand IgG1 and IVIg might not be a passive event but could induce ITAMi signaling. Therefore, we investigated whether Fc␥RIII targeting with a specific antibody or its natural ligand IgG might induce anti-inflammatory activity through ITAMi signaling. Our results show that such targeting induces a potent and long lasting ITAMi inhibitory signal that operates through murine as well as human Fc␥RIII-FcR␥ both in vitro and in vivo, revealing a previously unsuspected function of free IgG and IVIg, which is to dampen inflammatory responses and contribute to the regulation of tissue homeostasis.
Methods

Mice
BALB/c Fc␥RIIB Ϫ/Ϫ mice 24 were obtained from Taconics. BALB/c Fc␥RIIB Ϫ/Ϫ mice 10, 25 were kindly provided by S. Verbeek (Leiden University, The Netherlands). Homozygous viable motheaten (Ptpn6 meϪv ) mice (mev/mev) on C57BL/6 genetic background were generated as described. 26 Briefly, heterozygous viable motheaten (Ptpn6 meϪv ) mice (mev/ϩ) on C57BL/6 genetic background purchased from The Jackson Laboratory), were interbred to generate homozygous mev/mev mice which are deficient in SHP-1. 27 The genotype of the mice was determined following the protocols provided by The Jackson Laboratory.
Cell culture and reagents
Bone marrow-derived macrophages (BMMs) from 6-to 8-week-old mice were prepared. BMMs were obtained after a 7-day culture of bone marrow (BM) cells with colony-stimulating factor (CSF)-1. 28 RBL-2H3 mast cells expressing Fc␥RIII-FcR␥ chimeras were maintained in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 1 mg/mL G418 (Invitrogen). Human macrophages were obtained by bronchoscopy from healthy nonsmoking subjects at Bichat hospital with their informed consent in accordance with the Declaration of Helsinki and approved by the Bichat Ethical committee. Human peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers by Ficoll-Hypaque density gradient centrifugation. 24, 25 All experiments were performed in accordance with the Bichat Animal Facility guidelines and were approved by the Bichat Ethical committee. Rat anti-mouse (2.4G2) Fc␥RII/III, 29 mouse anti-human Fc␥RIII (3G8), 30 and irrelevant control mAbs were used as F(ab)Ј 2 and Fab fragments. F(ab)Ј 2 and Fab were prepared as described. 20, 31 Mouse anti-DNP-specific IgE (H1-⑀-26.82) was obtained as described. 32 Mouse monoclonal IgG1 was purified from hybridoma clone A62 as described. 20, 33 IVIg (Privigen; 100 mg/mL) was purchased from CSL Behring Gmbh.
Endocytosis and phagocytosis assays
For endocytosis, 5 ϫ 10 5 BMMs were allowed to adhere on chamber slides (Lab-tek 8 wells, Nalge Nunc International) and treated with lipopolysaccharide (LPS; 100 ng/mL) during 12 hours to induce MARCO expression. 34 Cells were washed and incubated with indicated Fc␥RIII targeting reagents and in some instances with goat anti-rat F(abЈ) 2 . After washing, Acetylated low-density lipoprotein (acLDL) endocytosis was induced by adding Alexa fluor 488-coupled acLDL (10 g/mL) for 30 minutes at 37°C. Cell surface was decorated by staining with biotinylated antibody to mouse CD11b (M1/70, Serotec) on ice for 20 minutes plus streptavidin-Alexa 568. To block acLDL endocytosis, cells were preincubated with 10 g/mL of anti-MARCO rat mAb ED31 (Serotec) for 30 minutes at 37°C. For phagocytosis, cells were allowed to adhere 8-well-chamber slides at 5 ϫ 10 5 cells per well for 12 hours and nonadherent cells were removed. Adherent cells were incubated with candidate F(abЈ) 2 (10 g/mL). Phagocytosis was initiated by incubation of Alexa Fluor 594-labeled Staphylococcus aureus (5 ϫ 10 5 per 10 6 bacteria; Molecular Probes) for 30 minutes at 37°C. Slides were mounted and examined with a confocal laser microscope (LSM 510 Carl Zeiss).
Measurement of ROS production
Blood human monocytes or neutrophils (5 ϫ 10 5 ) were purified from healthy donors and resuspended in 0.5 mL Hanks balanced salt solution (HBSS) containing 10M luminol (Sigma-Aldrich) with 3G8 F(abЈ) 2 at 5 to 10 g/mL or irrelevant 320 F(abЈ) 2 at 10 g/mL for 20 minutes. Cells were stimulated with 10 Ϫ6 M of N-formyl-methionine-leucine-phenylalanine (fMLF; Sigma-Aldrich). Chemiluminescence was recorded with a luminometer (Berthold-Biolumat LB937).
cDNA constructs, expression vectors, and transfection
The human Fc␥RIIIA sequence was amplified from plasmid pWX-puro Fc␥RIII LL 649 kindly provided by Dr L. Lanier (University of California, San Francisco). The Fc␥RIIIA-FcR␥ chimera was generated as follow. The extracellular domain of the human Fc␥RIII (F: TAGTCTAGATGGTGGT-GCAAATCAAAGAAC and R: GGCATCCAGGATATAGCAGAGTG-GAAAGAATGATGAGATGGTTG) as well as the transmembrane and intracellular domain of the human FcR␥ chain (F: CAACCATCTCAT-CATTCTTTCCACTCTGCTATATCCTGGATGCC and R: TAGGGATC-CCTACTGTGGTGGTTTCTCATG) were amplified by PCR. Products were fused by overlapping PCR. Fc␥RIIIA-FcR␥ chimeric sequences were cloned into XbaI-BamHI restriction sites (primers in bold) of pBJ1neo plasmid, derived from pcDL-SR␣-296, containing the SR␣ promoter. Point mutations (Y246F, Y257F, and Y246-257F) were introduced in the ITAM motif of the Fc␥RIIIA-FcR␥ chimera using Stratagene QuikChange site-directed mutagenesis kit. All constructs were verified by sequencing before transfection into RBL-2H3 cells by electroporation. Stable G418 resistant clones were selected, and Fc␥RIIIA expression levels and exocytosis capacity were determined.
␤-hexosaminidase assay
Exocytosis was determined by measuring release of the granule enzyme ␤-hexosaminidase as described. 35 Briefly, cells were sensitized overnight at 37°C with IgE anti-DNP (5 g/mL) and reagents were added as indicated in the figure legends. Exocytosis was induced by 0.1 g/mL DNP-HSA antigen (Sigma-Aldrich) at 37°C for 45 minutes. In some experiments, cells were directly incubated with candidate F(ab)Ј 2 (10 g/mL) on ice and degranulation was triggered at 37°C by addition of rabbit anti-mouse F(abЈ) 2 (RAM at 40 g/mL) for 45 minutes.
Immunoprecipitation and immunoblotting
Cells were solubilized in 1% digitonin-containing lysis buffer 20 and Fc␥RIII were immunoprecipitated for 2 hours at 4°C with either protein G 2 coupled to CNBr-activated sepharose 4B (AmershamPharmacia). Proteins were resolved by sodium dodecyl sulfate (SDS)-10% polyacrylamide gel electrophoresis (PAGE), transferred onto nitrocellulose membranes (Invitrogen) and immunoblotted with primary antibodies such as rabbit anti-SHP-1 (Biotrend), rabbit anti-Syk (Santa Cruz Biotechnology), rabbit anti-phospho-Erk MAPK (Cell Signaling Technology), rabbit anti-Erk (Santa Cruz Biotechnology), and rabbit anti-phospho-SHP1 (ECM Biosciences) followed by goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories) coupled to horseradish peroxidase (HRP). Membranes were developed by enhanced chemical luminescence (ECL) treatment (Amersham Biosciences).
Single cell calcium measurement
Cells were loaded with Fura2-AM in glass-bottom microwell dishes with 1M of Fura2-AM and pluronic acid (both from Invitrogen) and incubated at 37°C during 30 minutes. Cells were then washed with Ringer solution (in mM: 145 NaCl, 5.4 KCl, 2 CaCl2, 1 MgCl2, 10 glucose, 10 N-(hydroxyethyl)piperazine-NЈ-2-ethanesulfonic acid (HEPES) and 0.1% BSA, pH 7.5 with NaOH), or in some instances, in 5mM ethylene glycobis(b-aminoethyl ester)-N,N,NЈ,NЈ-tetraacetic acid (EGTA) solution (Ringer solution without calcium and buffered with 5mM EGTA). Cells were excited by wavelengths of 340 and 380 nm. Fluorescence emission of several cells was simultaneously recorded at a frequency of 1 Hz using a dual excitation mice were treated with lipopolysaccharide (LPS; 100 ng/mL) for 12 hours to induce MARCO expression. Cells were preincubated with 2.4G2 F(abЈ)2 anti-Fc␥RII/III (10 g/mL) or irrelevant rat IgG F(abЈ)2 for the indicated times at 37°C, followed by incubation with Alexa Fluor 488-coupled acLDL for 30 minutes to allow endocytosis. Cells were then stained with CD11b-biotin and streptavidin-Alexa 568 on ice for 20 minutes to delineate the cell surface before confocal microscopy. Scale bars: 5 m. (C) LPS-primed BMMs from Fc␥RIIB Ϫ/Ϫ or Fc␥RIII Ϫ/Ϫ were treated with irrelevant rat IgG F(abЈ)2 (10 g/mL) or with 2.4G2 F(abЈ)2 (10 g/mL) alone or 2.4G2 F(abЈ)2 plus goat anti-rat F(abЈ)2 (GAR at 40g/mL) for 30 minutes at 37°C and acLDL endocytosis was induced as before. Representative merged optical sections are presented showing internalized acDL inside the cells. Scale bars: 5 m. (B-D) Quantitative analysis of acLDL endocytosis experiments performed in panels A and C, respectively. Green mean fluorescence intensity (MFI) inside each cell was quantified using LSM510 analysis software that analyzes specific pixels in at least 5 confocal microscope fields (*P Ͻ .05, **P Ͻ .01, ***P Ͻ .001; n ϭ 5; nonparametric Mann-Whitney test).
fluorometric imaging system (TILL-Photonics) controlled by TILL-Vision Version 4.0 software. Signals from approximately 30 cells were computed into relative ratio units of the fluorescence intensity of the different wavelengths (340/380 nm).
Inhibisome formation
Cells were allowed to adhere in 8-well-chamber slides for 12 hours at 37°C. Cells were sensitized for 1 hour with Alexa Fluor 488-conjugated anti-DNP IgE (5 g/mL) and incubated for 30 minutes with biotinylated 3G8 anti-Fc␥RIII F(ab)Ј 2 (10 g/mL) before the addition of DNP-HSA for 10 minutes. Cells were successively fixed (with 3% paraformaldehyde), permeabilized (with 0.025% saponin), and saturated nonspecific sites, before incubation with rabbit anti-SHP-1 polyclonal antibodies (Santa Cruz Biotechnology) and the relevant secondary antibodies (cross-adsorbed anti-rabbit Alexa Fluor 647-conjugated goat antibody, and Alexa Fluor 568-conjugated steptavidin; Molecular Probes). Cells were mounted and examined with a confocal laser microscope (LSM 510 Carl Zeiss). Data were analyzed with LSM 510 image examiner software (W. Rasband, National Institutes of Health).
Flow cytometry
Cells were preincubated or not with 100 g human IgG to block Fc␥Rs before incubation with biotinylated anti-human Fc␥RIII 3G8 or irrelevant mAb plus streptavidin (SA)-PE (Sourthern Biotech Associates). After washing, cells were analyzed by FACScalibur flow cytometer and FlowJo Version 7.6.3 software (BD Biosciences).
Unilateral ureteral obstruction nephritis model
Nephritis was induced by unilateral ureteral obstruction (UUO) as described. 36 Animals were injected intraperitoneally with 100 g/20 g body weight of 2.4G2 F(ab)Ј 2 or of rat IgG F(ab)Ј 2 , or with 40 mg/20 g body weight of IVIg or of BSA, for 8 days at 48-hour intervals. The first dose was administered 24 hours before UUO. On day 8, animals were killed and kidneys were analyzed.
Immunohistochemistry
Acetone-fixed frozen kidney sections (3 to 4-m-thick) were incubated with biotinylated rat anti-mouse mAb CD11b (BD Pharmingen) as described. 37 Infiltrating CD11bϩ cells were counted blind under a microscope (Leica Microsystems) using a 40ϫ objective. A minimum of 30 high-power fields (HPFs) were analyzed and data are expressed as cells/HPF.
Quantitative real-time PCR analysis
Kidneys were homogenized and RNA was prepared. RNA (100 ng) was reverse-transcribed using SuperScript III reverse transcriptase (Invitrogen). Resulting cDNA was used as template for qPCR analysis. Primers were purchased from Eurofins and were as follows: GAPDH: 5Ј-ACG-GCAAATTCAACGGCACAGTCA-3Ј (sense), 5Ј-TGGGGGCATCGGCA-GAAGG-3Ј (antisense); MCP-1: 5Ј-ATGCTTCTGGGCCTGCTGTTC-3Ј(sense), 5Ј-CTGCTGCTGGTGATCCTCTTGTAG-3Ј (antisense); TNF␣: 5Ј-AGGCACTCCCCCAAAAGATG-3Ј (sense), 5Ј-TCACCCCGAAG-TTCAGTAGACAGA-3Ј (antisense). Gene quantification was performed in duplicate on Chromo4 Real-Time PCR Detection System (Biorad). Data were normalized to GAPDH values.
Results
Identification of mouse Fc␥RIII as an inhibitory receptor after IgG1 and IVIg binding
As IgG binds to several Fc␥Rs, we first addressed whether specific targeting of mouse Fc␥RIII using an anti-Fc␥RII/III (2.4G2) antibody could inhibit MARCO-mediated endocytosis by BMMs.
To exclude effects of ITIM-bearing Fc␥RIIB, which is also recognized by 2.4G2, BMMs from Fc␥RIIB-deficient mice (Fc␥RIIB Ϫ/Ϫ ) were used. acLDL is a known ligand of the scavenger receptor MARCO. 38 Neither expression of MARCO nor MAR-CO's ability to promote acLDL endocytosis were altered by the absence of Fc␥RIIB or of Fc␥RIII on BMM (supplemental Figure  1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article). Preincubation of BMMs from Fc␥RIIB Ϫ/Ϫ mice with 2.4G2 F(abЈ) 2 for 10 minutes to 2 hours inhibited acLDL endocytosis compared with irrelevant F(abЈ) 2 fragments ( Figure 1A-B) . The inhibition of endocytosis occurred in a time-dependent manner reaching the maximal level at 30 minutes preincubation with the antibody. F(abЈ) 2 -mediated inhibition (2.4G2) was abolished in Fc␥RIII Ϫ/Ϫ BMMs (Figure 1-D) confirming that Fc␥RIII was the receptor that mediated this inhibitory signal. Inhibition was not observed with 2.4G2 Fab, instead of F(abЈ) 2, fragments (supplemental Figure 2) , which indicates that at least for 2.4G2, antibody-mediated inhibition might occur only when Fc␥RIII is dimerized. In contrast, further crosslinking of Fc␥RIII on Fc␥RIIB Ϫ/Ϫ BMMs failed to induce inhibition ( Figure 1C-D) , which indicates that, as for Fc␣RI, ITAMi function cannot be activated when receptors are extensively aggregated. In agreement with data showing that Fc␥RIIB can inhibit BCR signaling without coligation, 39 multimerization of ITIM-bearing Fc␥RIIB in Fc␥RIII Ϫ/Ϫ BMMs by 2.4G2 F(abЈ) 2 plus goat anti-rat F(abЈ) 2 inhibited acLDL endocytosis without coligation between Fc␥RIIB and MARCO. These results underscored that ITIM-and ITAMbearing receptors mediate inhibition through different pathways.
To explore whether natural ligands of mouse Fc␥RIII are able to mediate inhibitory signaling, we evaluated endocytosis of acLDL by BMMs from either Fc␥RIIB Ϫ/Ϫ or Fc␥RIII Ϫ/Ϫ mice in the presence of a monomeric fraction of a mouse monoclonal IgG1. Monomeric IgG1 inhibited acLDL endocytosis in Fc␥RIIB Ϫ/Ϫ BMMs and this inhibition was abolished in the absence of Fc␥RIII (Figure 2A-B) . This inhibition was dose dependent, reaching a significant effect at 10 mg/mL IgG1 ( Figure 2 ). It was not observed in cells expressing Fc␥RIIB in the absence of Fc␥RIII even at IgG1 concentrations similar to those found in serum ( Figure 2B ). These experiments allowed us to conclude that only high concentrations of monomeric IgG1, which resemble polyclonal IgG1 concentrations in the plasma, can trigger an Fc␥RIII-dependent inhibitory pathway. The fact that inhibition was fully abolished in Fc␥RIII Ϫ/Ϫ BMMs excludes other Fc␥ receptors, such as Fc␥RI and Fc␥RIV, as molecular targets of IgG1-inhibitory signals.
As monomeric monoclonal mouse IgG1 mediated inhibition through Fc␥RIII, we next investigated whether IVIg, which contain mainly IgG1, can similarly induce an inhibitory signal via Fc␥RIII. Preincubation of Fc␥RIIB Ϫ/Ϫ , but not Fc␥RIII Ϫ/Ϫ , BMMs with high concentrations of IVIg significantly inhibited acLDL endocytosis whereas irrelevant control BSA had no effect ( Figure 3A , supplemental Figure 3) . Likewise, direct targeting of Fc␥RIII on these cells by 2.4G2 F(abЈ) 2 , but not its extensive aggregation by 2.4G2 F(abЈ) 2 immune complexes, inhibited acLDL endocytosis ( Figure 3A , supplemental Figure  3 ). As IVIg can form multimeric species with donor or host IgG including mainly so called IgG dimers, 40 HPLC-purified fractions containing mononeric (IVmIg), or dimeric (IVdIg) IVIg (supplemental Figure 4) were prepared to address their effect on the blockade of acLDL endocytosis in Fc␥RIIB Ϫ/Ϫ BMMs ( Figure 3B ). These experiments indicated that polyclonal human 
Inhibitory function of human Fc␥RIIIA is mediated by the FcR␥ ITAM
Both mouse Fc␥RIII and its human homolog, the Fc␥RIIIA, are associated with the ITAM-bearing adaptor FcR␥. 7 Therefore, we next assessed whether human Fc␥RIIIA was also able to induce inhibition after specific targeting by F(abЈ) 2 anti-human Fc␥RIII (3G8). Preincubation of human alveolar macrophages, which express both Fc␥RIIIA and MARCO (supplemental Figure 5) , with 3G8 F(abЈ) 2 inhibited MARCO-mediated phagocytosis of S aureus ( Figure 4A ).
Because monocytes express FcR␥-associated Fc␥RIIIA, whereas neutrophils express the signaling incompetent GPI-anchored Fc␥RIIIB, 41 we next examined Fc␥RIII-inhibitory signaling in both cell types. The formylated peptide f-Met-Leu-Phe (fMLF), derived from bacteria, was used as a stimulus as it induces ROS production in both monocytes 42 and neutrophils. 43 Preincubation of monocytes with 3G8 F(abЈ) 2 inhibited fMLF-mediated ROS production in a dose-dependent manner whereas irrelevant F(abЈ) 2 had no effect ( Figure 4B ). By contrast, preincubation of human neutrophils with 3G8 F(abЈ) 2 failed to inhibit response to fMLF ( Figure  4C ), which indicates that inhibition required the Fc␥RIIIA-associated FcR␥ signaling adaptor.
To demonstrate whether the inhibitory function involves an ITAMi-mediated mechanism, 18 wild-type (WT) and mutant Fc␥RIII-FcR␥ chimera were generated ( Figure 5A top panel) and transfected into the rat mast cell line RBL-2H3 yielding significant level of expression at the cell surface ( Figure 5A bottom panels) . As RBL-2H3 mast cells express Fc⑀RI, we evaluated inhibition by the transfected chimeric receptors of IgE-dependent exocytosis. Preincubation of WT transfectants with anti-human Fc␥RIII 3G8 F(abЈ) 2 , but not with irrelevant 320 F(abЈ) 2 , markedly inhibited Green MFI inside each cell was quantified using LSM510 analysis software that analyzes specific pixels in at least 5 confocal microscope fields (*P Ͻ .05, **P Ͻ .01, ***P Ͻ .001; n ϭ 5; nonparametric Mann-Whitney test).
IgE-dependent cell degranulation ( Figure 5B ). This effect was abolished in double, as well as single, Y-to-F FcR␥ ITAM mutant transfectants, which shows that both tyrosine residues are involved in the inhibitory process. Furthermore, multimeric crosslinking could induce Fc␥RIII-mediated exocytosis in WT but not in mutant transfectants RBL-2H3 cells ( Figure 5C ). These results indicate that, similar to the activating response, the inhibitory responses through Fc␥RIIIA are ITAM-dependent. We next evaluated whether human polyclonal IgG (IVIg preparations) could also inhibit mast cell exocytosis in transfectants expressing the Fc␥RIIIA-FcR␥ chimera. Figure 5D shows that, as previously described, only high concentrations of IVIg (Ͼ 5 mg/mL) were able to inhibit Fc⑀RI degranulation. Morever, Fc␥RIII-FcR␥ chimera-mediated IVIg action required 2 hours to be optimal, whereas inhibition mediated by 3G8 F(abЈ) 2 anti-Fc␥RIII was already maximal at 30 minutes.
This suggests that besides the degree of aggregation of the Fc␥RIII ligands, their affinity for the receptor ligand is another important parameter that controls the inhibitory function of Fc␥RIII.
Analysis of ITAMi inhibitory signaling by Fc␥RIIIA
We have shown previously that ITAMi signaling via Fc␣RI involves a series of specific signaling responses that explain the ITAMi-mediated inhibitory actions. To identify whether IgG or antibody-mediated targeting of Fc␥RIII induced similar inhibitory signaling, we used RBL-2H3 transfectants expressing Fc␥RIII-FcR␥ chimera. Figure 6A shows that preincubation with either IVIg or 3G8 F(abЈ) 2 , but not irrelevant 320 F(abЈ) 2 (supplemental Figure 6) , induced a transient recruitment (up to 30 minutes) of Syk to the chimera, which was followed by stable recruitment (at least . Alexa Fluor 488-coupled acLDL was added to allow endocytosis for 30 minutes followed by plasma membrane staining using anti-CD11b-biotin and streptavidin-Alexa 568 before confocal analyses. Left panels show representative merged optical sections of internalized acDL inside the cell. Scale bars: 5 m. Right panel indicates quantification of acLDL endocytosis using green MFI inside each cell as quantified by LSM510 analysis software that analyzes specific pixels in at least 5 confocal microscope fields (**P Ͻ .01; nonparametric Mann-Whitney test). (B) LPS-primed BMMs from Fc␥RIIB Ϫ/Ϫ mice were preincubated with 10 mg/mL unfractionnated IVIg, with HPLC-purified monomeric (IVmIg) or HPLC-purified dimeric IVIg (IVdIg) or BSA as a control. Cells were also preincubated with 10 g/mL of 2.4G2 F(abЈ)2 or immune complexes (IC) made of 2.4G2 F(abЈ)2 (10 g/mL) plus goat anti-rat F(abЈ)2 (GAR at 40g/mL) for 30 minutes at 37°C. Endocytosis was induced by addition of Alexa Fluor 488-coupled acLDL. The plasma membrane was stained with CD11b-biotin and streptavidin-Alexa 568 on ice for 20 minutes and cells were analyzed using confocal microscopy. Representative merged optical sections are presented showing internalized acDL inside the cell. Scale bars: 5 m. Green mean fluorescence intensity (MFI) inside each cell was quantified (right panel) using LSM510 image examiner software that analyzes specific pixels in at least 5 confocal microscope fields (**P Ͻ .01; n ϭ 5; nonparametric Mann-Whitney test).
IgG1 AND IVIg INDUCE Fc␥RIII-ITAMi SIGNALING 3089 BLOOD, 29 MARCH 2012 ⅐ VOLUME 119, NUMBER 13 For personal use only. on April 15, 2017. by guest www.bloodjournal.org From up to 6 hours) of SHP-1. Interestingly, in agreement with the delayed action of IVIg ( Figure 5D ), the kinetics of recruitment of these signaling effectors was also delayed after IVIg treatment compared with 3G8 F(abЈ) 2 . The recruitment of SHP-1 was accompanied by the concomitant phosphorylation of SHP-1. In Fc␥RIIB Ϫ/Ϫ BMMs the situation was slightly different in that both Syk and SHP-1 were already constitutively associated with endogenous Fc␥RIII in unstimulated cells (data not shown) as previously observed. 23 Again, preincubation with IVIg or 2.4G2 F(abЈ) 2 enhanced recruitment of these effectors (data not shown). These experiments indicate that Fc␥RIII targeting induced an ITAMi configuration characterized by activation and recruitment of the negative signaling effector SHP-1. Furthermore, Fc␥RIII ITAMi configuration was able to block the IgE-dependent MAP-kinase pathway in transfectants that express the Fc␥RIII-FcR␥ chimera, as demonstrated by inhibition of ERK phosphorylation after IVIg or 3G8 F(abЈ) 2 treatment (supplemental Figure 7) . Of note, IVIg and 3G8 F(abЈ) 2 had no effect on the IgE-dependent Erk-signaling pathway in nontransfected RBL-2H3 cells indicating that this inhibition required relevant Fc␥RIII expression. To demonstrate the role of SHP-1 in mediating ITAMi signaling through mouse or human Fc␥RIII, we used either BMMs from SHP-1 deficient mice (mev/mev) or RBL-2H3 transfectants expressing Fc␥RIII-FcR␥ chimera after specific knockdown of SHP-1. In both cases, IVIg failed to induce inhibition through Fc␥RIII in the absence of SHP-1 compared with controls ( Figure 6B , supplemental Figure 8 ). As intracellular calcium mobilization is required for cell activation, 44 we next assessed whether the increase in intracellular calcium concentration ([Ca 2ϩ ] i ), was impaired by either 3G8 F(ab) 2 or IVIg treatment. Fc⑀RI-mediated stimulation readily induced Ca 2ϩ influx in Fura-2-AM-loaded Fc␥RIII-FcR␥ transfectants. This response was markedly inhibited by preincubation with either 3G8 F(abЈ) 2 or IVIg compared with irrelevant controls ( Figure 6C ). Of note, Ca 2ϩ mobilization was more strongly inhibited by 3G8 than IVIg in agreement with strong inhibitory effect on endocytosis or phagocytosis. No inhibitory effect on Ca 2ϩ entry was observed by either 3G8 F(abЈ) 2 or IVIg in untransfected cells and in transfectants bearing ITAM-mutated forms (supplemental Figure 9) , clearly indicating ITAM dependency of inhibitory responses. To discriminate between calcium release from intracellular stores and calcium entry from external medium, cells were treated with the calciumchelating agent EGTA shortly before stimulation with antigen. Intracellular calcium mobilization under these conditions was strongly reduced by 3G8 F(abЈ) 2 treatment (supplemental Figure  10 ). This inhibition was not observed in nontransfected cells, which show that inhibition mediated by Fc␥RIII was upstream to the calcium release from intracellular stores.
ITAMi signaling has been shown in the case of Fc␣RI to involve formation of polarized intracellular clusters named "inhibisomes," which enable ITAMi-recruited SHP-1 to target activating receptors independent of coligation at the cell surface. 22 We examined whether Fc␥RIII ITAMi signaling similarly induced intracellular coclustering with the targeted Fc⑀RI. Confocal analysis showed that 3G8 F(abЈ) 2 targeting of Fc␥RIII induced the codistribution of Fc␥RIII and Fc⑀RI in intracellular clusters as typical inhibisomes ( Figure 6D ). As expected for such structures, the inhibitory SHP-1 phosphatase was colocalized with these receptors.
Relevance of Fc␥RIII inhibitory targeting in vivo by IVIg or anti-Fc␥RIII antibodies
To demonstrate the role of ITAMi-mediated Fc␥RIII-dependent inhibition in vivo, we chose to use IVIg in an antibody-independent inflammatory model of obstructive nephropathy after UUO. 21, 36 This strategy allowed to exclude competition effects of IVIg on Fc␥Rs involved in models of IgG immune-complex-mediated autoimmune diseases. 1 Targeting Fc␥RIII ITAMi in UUO model also allowed to investigate whether heterologous receptors such as chemokine and cytokine receptors were inhibited as is the case for Fc␣RI. 21 We first analyzed the effect of 2.4G2 F(abЈ) 2 , which directly targeted Fc␥RIII in the background of Fc␥RIIB-deficiency, and induced similar to 3G8 (Figure 6 ), phosphorylation of SHP-1 in Fc␥RIIB Ϫ/Ϫ BMM (supplemental Figure 11) . In vivo, treatment with 2.4G2 F(abЈ) 2 markedly reduced inflammatory cell infiltrates in the obstructed kidney of Balb/c Fc␥RIIB Ϫ/Ϫ mice ( Figure 7A ). This anti-inflammatory effect was not observed in Fc␥RIII Ϫ/Ϫ mice (data not shown) indicating that Fc␥RIII mediates a major inhibitory function. Morever, IVIg treatment was also able to prevent macrophage infiltration to the obstructed kidney of Balb/c Fc␥RIIB Ϫ/Ϫ mice, and again this inhibition was not observed in the absence of Fc␥RIII ( Figure  7A bottom panels) .
Further examination of the proinflammatory response showed that expression levels of cytokine transcripts such as MCP-1 and TNF␣ in kidneys after UUO were also markedly down-regulated both after 2.4G2 F(abЈ) 2 and IVIg treatment ( Figure 7B ). Again, this anti-inflammatory effect was not observed in Fc␥RIII Ϫ/Ϫ mice, which rule out inhibition through other FcRs in the absence of coligation ( Figure 7B ). Together, these results indicate that targeting of Fc␥RIII by either anti-Fc␥RIII F(abЈ) 2 or IVIg has a remarkable anti-inflammatory effect by limiting proinflammatory (B) IgE-sensitized RBL-2H3 transfectants were incubated with either 3G8 F(abЈ)2 or 320 F(abЈ)2 at 10 g/mL for 30 minutes at 37°C as indicated and degranulation was triggered with DNP-HSA (0.1 g/mL) for 45 minutes. Net ␤-hexosaminidase release was determined. (*P Ͻ .05; n ϭ 3; nonparametric Mann-Whitney test). (C) RBL-2H3 transfectants were incubated with 10 g/mL of 3G8 F(abЈ)2 at 4°C before stimulation with rabbit anti-mouse F(abЈ)2 (RAM at 40 g/mL) for 45 minutes at 37°C. Net ␤-hexosaminidase release was determined. (**P Ͻ .01; n ϭ 3; nonparametric Mann-Whitney test). (D) IgE-sensitized huFc␥RIII ϩ RBL-2H3 transfectants were preincubated at 37°C with either BSA at 10 mg/mL for 240 minutes or 3G8 F(abЈ)2 or with IVIg, at the indicated concentrations and for the indicated time. Degranulation was measured as in panel B (*P Ͻ .05; n ϭ 3, nonparametric Mann-Whitney test).
IgG1 were incubated with either 3G8 F(abЈ)2 (10 g/mL) or IVIg (10 mg/mL) for the indicated times at 37°C. Cells were solubilized in 1% digitonin lysis buffer and immunoprecipitated with sepharose-coupled protein G sepharose (left panel) or with 3G8 F(abЈ) 2 fragment coupled to CNBr-activated sepharose 4B (right panel), and then immunoblotted (IB) with anti-SHP1 or anti-Syk antibodies. Total lysates were analyzed for SHP-1 phosphorylation by immunoblotting with anti-phospho-SHP-1 (p-SHP1) antibody. The amounts of SHP-1 and Syk in lysates were analyzed in parallel using anti-SHP-1 or anti-Syk antibodies. (B) LPS-primed BMMs from WT and mev/mev mice were incubated with IVIg (18 mg/mL) or with BSA (18 mg/mL) for 30 minutes at 37°C. Alexa Fluor 488-coupled acLDL was added to allow endocytosis for 30 minutes followed by plasma membrane staining using anti-CD11b-biotin and streptavidin-Alexa 568 before confocal analyses. Left panels show representative merged optical sections of internalized acLDL inside the cell. Scale bars: 5 m. Right panel indicates quantification of acLDL endocytosis using green MFI inside each cell as quantified by LSM510 analysis software that analyzes specific pixels in at least 5 confocal microscope fields (**P Ͻ .01; nonparametric Mann-Whitney test). Data are representative for at least 3 independent experiments. (C) IgE-sensitized huFc␥RIII ϩ RBL-2H3 transfectants were incubated with either 3G8 F(abЈ)2 (10 g/mL) or IVIg (10 mg/mL) for 30 minutes at 37°C. Free intracellular Ca 2ϩ was assessed after cell activation with DNP-HSA (0.1 g/mL). After 7 minutes transfectants were stimulated with 1M ionomycin to determine maximal calcium uptake (n ϭ 30 cells in each group). (D) Alexa 488-IgE sensitized huFc␥RIII ϩ RBL-2H3 transfectants were incubated for 30 minutes with etheir biotinylated 3G8 F(abЈ)2 or biotinylated 320 F(abЈ)2 at 10 g/mL before addition of DNP-HSA antigen for 10 minutes. Cells were then fixed, permeabilized and further incubated with rabbit anti-SHP-1 antibodies followed by goat anti-rabbit Alexa Fluor 647. For detection of Fc␥RIII, Alexa Fluor 568-conjugated steptavidin was used. Receptors (Fc⑀RI in green, Fc␥RIII in red) and SHP-1 (in blue) were analyzed by confocal microscopy. DIC and representative single optical sections through individual cells, as well as the merged images (xy planes), are presented. Scale bars: 5 m. Data are representative of at least 3 independent experiments. cytokines production in antibody-independent obstructive kidney inflammatory disease.
Discussion
At present, IgG isotypes have been considered as major actors in adaptive immune responses by their capacity to eliminate antigens through their combined interaction with antigen and either complement or multiple Fc␥Rs. 45 Effector mechanisms depend on antigen recognition and formation of immune complexes. However, even in the absence of specific antigen at the concentrations present in serum, IgGs continuously interact with their corresponding receptors through the Fc domains. In the past, these interactions have been considered as without biologic consequences. Here, we provide clear evidence that the interaction of IgG with Fc␥RIII, For personal use only. on April 15, 2017. by guest www.bloodjournal.org From independently of antigen, can induce cell signaling through the ITAM with an overall inhibitory function toward a variety of heterologous activating receptors in the absence of coaggregation. Monomeric or dimeric targeting of mouse Fc␥RIII by either mouse IgG1, human IVIg, or anti-Fc␥RIII F(abЈ) 2 reduced MARCOdependent acLDL endocytosis in primary macrophages. Recent evidence showed that E coli binding to mouse Fc␥RIII in an IgG-independent manner induces ITAMi signaling through this receptor that blocks MARCO-mediated phagocytosis thereby favoring immune evasion of the bacteria. 23 The present data suggest an opportunistic use of a physiologic inhibitory mechanism by E coli. More importantly, they also support the notion that Fc␥RIII mediates a dual activating and inhibitory function depending on the degree of aggregation of its natural ligand IgG. This inhibitory action of Fc␥RIII was not restricted to phagocytosis but affected also inflammatory mediator release. Indeed, IVIg or anti-human Fc␥RIII F(abЈ) 2 inhibited IgE-mediated exocytosis in RBL-2H3 cells transfected with human Fc␥RIII-FcR␥ chimera as well as fMLF-mediated ROS production from isolated human blood monocytes. The observation that GPI-anchored Fc␥RIIIB on human neutrophils failed to mediate such functions was a strong indication of FcR␥ involvement. This was further demonstrated by experiments using human Fc␥RIII-FcR␥ fusion proteins. Analysis of the signaling mechanism using these transfectants clearly revealed an ITAMi configuration, similar to what has been observed for Fc␣RI by IgA and for Fc␥RIII by E coli. 20, 23 ITAM involvement was demonstrated by analysis of tyrosine point mutations of the ITAM associated with the receptor chimeras as either of the 2 tyrosines was found necessary to generate the suppressive signal. Furthermore, as for Fc␣RI, both Syk and SHP-1 were recruited under inhibitory conditions. Kinetic analysis revealed 2 consecutive phases involved in inhibitory ITAMi signaling as previously predicted 46 : a preactivating phase characterized by the early and transient recruitment of Syk followed by stable recruitment of the inhibitory effector, SHP-1, which coincided with the appearance of the inhibitory action. The abolishment of inhibition in single Y-to-F FcR␥-ITAM mutant transfectants indicate that both tyrosine residues are required to SHP-1 recruitment to Fc␥RIII, which is in agreement with a previous observation that SHP-1 binding to inhibitory natural killer (NK) receptors requires tyrosine phosphorylation in 2 ITIM sequences. 47 This was observed for both anti-Fc␥RIII F(abЈ) 2 and IVIg ligands. SHP-1 recruitment also coincided with its phosphorylation on tyrosine 536 known to enhance its activity. 48 Kinetics of effector recruitment and SHP-1 phosphorylation was delayed after IVIg treatment compared with anti-Fc␥RIII antibody, in agreement with the lower affinity of IgG ligand for Fc␥RIII. SHP-1 is a major inhibitory effector of this ITAMi signaling as specific knockdown of this phosphatase reversed the inhibitory effect. In agreement with SHP-1 dependent action, we found a strong inhibition of the IgE-mediated Erk phosphorylation and calcium mobilization. Release of intracellular calcium stores was blocked by Fc␥RIII targeting indicating that the inhibitory receptor pathway initiated by ITAMi could affect multiple heterologous receptor signal transduction that rely on cytosolic calcium increases. In agreement with a local action, we identified inhibitory and activating receptors colocalized in intracellular structures previously defined as inhibisomes, 22 which enable local negative regulation by SHP-1 in absence of receptor coligation at the cell surface. These findings confirm inhibisomes as relevant cellular structures of ITAMi signaling. Interestingly, SHP-1 recruitment and phosphorylation is only observed after stimulation in RBL transfectants expressing human Fc␥RIII-␥ chimera. This differs from what is observed in mouse cells expressing endogenous Fc␥RIII. Indeed, our previous data showed that mouse Fc␥RIII expressed by macrophages is constitutively in an ITAMi configuration through constitutive phosphorylation of associated FcR␥ and recruitment of SHP-1 and syk 23 by a mechanism still unknown that may involve a yet unidentified cis-acting self-ligand. Still, targeting of Fc␥RIII with E coli increases this ITAMi configuration. 23 Independent of these considerations, constitutive phosphorylation and association of SHP-1 is not sufficient for inhibisome formation as this requires a second event provided by the stimulation of activating receptor and their engagement in rafts domain. 22 The inhibitory action was optimal at high concentrations of IgG (ϳ10 mg/mL that is in the 10 Ϫ4 -10 Ϫ5 M range) that coincide with IgG concentrations found in serum in humans, which supports that this may be relevant in vivo. This is also in agreement with the fact that monomeric IgG1 binds Fc␥RIII through a low-affinity interaction with a k D Ͼ 10 Ϫ6 M. 49 It should be noted that IVIg consists of at least 90% intact IgG, with inhibitory IgG1 being the major component in IVIG preparations. 2, 5 Furthermore, the therapeutic doses used in the treatment of autoimmune and inflammatory diseases (in the range of 400 mg/kg/d) 5 will increase IgG1 plasma levels, therefore shifting the balance toward an inhibitory mode of Fc␥RIIIA, as observed in our dose-response experiments. The fact that IgG dimers that also present in IVIg preparations or anti-Fc␥RIII F(abЈ) 2 , but not multimers, induced such inhibitory signals is in support of the requirement of either monovalent or divalent interaction with Fc␥RIII. In this context, it is interesting to note that bivalent interaction with F(ab)Ј 2 antibodies showed a more rapid kinetics to reach inhibition compared with monomeric IgG, possibly because of the higher affinity of Fc␥RIII-specific antibodies. Strikingly, and in contrast to what has been observed for Fc␣RI, 20 anti-Fc␥RIII 3G8 Fab were ineffective in inducing inhibition. However, it should be noted that 1 of 4 anti-Fc␣RI Fab tested were unable to induce inhibition, 20 which suggests that conformational changes induced by some, but not all, specific antibodies may be important in the Fc␣RI inhibitory system. Whether such conformational changes are actually induced in Fc␣RI and Fc␥RIII by their respective monomeric ligands remain to be determined.
IVIgs are currently used for treatment of inflammatory and autoimmune diseases. Several mechanisms have been proposed for IVIg action, including ITIM-mediated Fc␥RIIB inhibitory signals 1,2 or involving DC-SIGN for a minor population of IgG. 6 A role for Fc␥RIII in IVIg-mediated inhibition has been reported in 2 studies 14,15 implicating activation of Fc␥RIII by large IgG immune complexes. Although Park-Min et al found that Fc␥RIII activation leads to the suppression of IFN-␥ signaling by downregulating expression of the IFNGR2 subunit of the IFN-␥ receptor, 15 Siragam et al showed priming of regulatory activity by dendritic cells as the responsible mechanism. 14 Regulatory iNKT cells may also mediate IVIg-induced anti-inflammatory actions. 16 However, the implication of Fc␥RIII ITAMi in this inhibition has not been investigated. Both IVIg and 2.4G2 anti-Fc␥RII/III F(abЈ) 2 treatments were beneficial to prevent inflammation by reducing tissue macrophage infiltration and inflammatory mediator production in an inflammatory model of obstructed kidney in Fc␥RIIB Ϫ/Ϫ mice. This reduction was observed in the background of Fc␥RIIB deficiency, but completely absent in the Fc␥RIII deficiency, clearly establishing the importance of Fc␥RIII targeting. These in vivo data further confirm the capacity of ITAMi signaling to inhibit a wide array of heterologous receptors. This efficient prevention of an IgG-independent inflammatory reaction in vivo by targeting Fc␥RIII establishes a rationale for a new line of therapeutic strategies with a wide range of applications. In addition, the more rapid inhibition observed after anti-Fc␥RIII F(abЈ) 2 treatment than after IVIg treatment opens the possibility for an alternative approach to IVIg than remains to be fully evaluated. Thus, our data point out a new mechanism of IVIg action, which involves ITAMi signaling via Fc␥RIII.
In summary, our conclusion that IVIg and IgG1 control inflammatory response by ITAMi signaling through Fc␥RIII is based on the following evidences: (1) in vitro targeting of Fc␥RIII with irrelevant IgG1 through its Fc portion inhibited endocytosis in a dose-dependent manner that reflects the IgG concentration found in serum; (2) in vitro targeting of Fc␥RIII with F(abЈ) 2 fragments of specific antibodies had the same effect as IgG, whether in mouse or in human cells, whereas targeting Fc␥RII did not although it has the same extracellular domain as Fc␥RIII; (3) 2 fragments of specific antibodies was as efficient in preventing inflammation in the UUO model as IVIg acting through Fc␥RIII; and (6) the Fc␥RIII-mediated inhibitory signaling had all the biochemical hallmarks of an ITAMi signaling. We conclude that targeting Fc␥RIII in vivo either with IVIg (whether by natural antibodies present in the preparations or by Fc binding) or with an F(abЈ) 2 fragment of specific antibodies may have therapeutic relevance. However, it should be stressed that Fc␥RIII targeting is not the only means of action of IVIg because others have convincingly reported other ways of action for these immunoglobulins. 1, [3] [4] [5] [6] Thus, although VIg may use multiple and nonexclusive modes of action, Fc␥RIII targeting is one of these modes that could have potent therapeutic development.
Evolution might have designed multiple ways (both positive and negative) of controlling activation of the immune system. This system has powerfully destructive potential that needs to be properly kept in check for adapted immune responses. Thus, in the absence of antigen the immune system may not be dormant but constantly under control through interaction of large numbers of monomeric immunoglobulins with their cognate receptors. Introduction of antigens would shift this situation through multimeric interaction of immune complexes with Fc␥RIII that would both induce activating signals and weaken the inhibitory signals through a decrease in available Fc␥RIII for monomeric IgG binding. In this setting, ITIM signaling (through coaggregation of Fc␥RIIB and Fc␥RIII by immune complexes) would relay in part ITAMi signaling for inhibition; this relay growing in intensity when the ITAMi signal would weaken after raising levels of circulating immune complexes. Altogether, our data support a new paradigm of immune homeostasis regulation by monomeric IgG. 
